C3.ai's (NYSE:AI) stock tumbled 10% on Sept. 2 after the artificial intelligence software provider posted its first-quarter earnings. Its revenue rose 29% year-over-year to $52.4 million, beating estimates by $1.1 million. It posted a net loss of $37.5 million -- compared to a slim profit of $150,000 a year ago -- but its loss of $0.37 per share still matched Wall Street's expectations. Should investors buy C3 after its post-earnings plunge? Or is it still overvalued even after plummeting more than 70% from its 52-week high?

-- Predicting s ales opportunities outcome is a core to successful business management and revenue forecasting . Conventionally, this prediction has relied mostly on subjective human evaluations in the process of business to business (B2B) sales decision making. Here, we proposed a practical Machine Learning (ML) workflow to empower B2B sales outcome (win/lose) pre diction within a cloud - based computing platform: Microsoft Azure Machine Learning Service (Azure ML). This workflow consists of two pipelines: 1) a n ML pipeline that trains probabilistic predictive models in parallel on the closed sales opportunities data enhanced with an extensive feature engineering procedure for automated selection and parameterization of an optimal ML model and 2) a Prediction pipeline that uses the optimal ML model to estimate the likelihood of win n ing new sales opportunities as well a s predicting their outcome using optimized decision boundaries. The p erformance of the proposed workflow was evaluated on a real sales dataset of a B2B consulting firm. In the Business to Business (B2B) commerce, companies compete to win high - valued sales opportunities to maximize their profitability. In this regard, a key factor for maintain ing a successful B2B business is the task of determining the outcome of sales opportunities.

The original contract in Alzheimer's disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May 2021 and the addition of new clinical sites. Change orders often occur as part of the normal course of multi-year contracts, as the scope of services that IXICO provides can be expanded or extended during the term of a clinical trial. IXICO CEO Giulio Cerroni said: "We are delighted to announce a further extension and expansion of this project. This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes." IXICO is dedicated to delivering insights in neuroscience.

SirionLabs, a startup providing vendor management software to enterprises, is adding a US headquarters to its footprint. The company was initially founded in India and has raised $16.95 million from Sequoia Capital India, Canopy Ventures and Qualgro VC to extract data from contracts to ensure transparency and accountability. The establishment of a US presence represents a strategic shift in the company's growth plans. Last year, SirionLabs told TechCrunch that it was looking to hire and relocate workers from Silicon Valley to India. While the startup has had offices in the UK, Germany, Denmark and Singapore, it has been slow to establish a permanent US team.